Eln 2022 risk aml | oncology Calculator

Recent Journal Updates

Intensive Care MedicineJun 8, 2026

International evidence-based recommendations for point-of-care lung ultrasound

Clinical Context

We think this has broad domain relevance to ELN 2022 Risk Stratification (AML).

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for ELN 2022 Risk Stratification (AML).

Emerging Infectious DiseasesJun 2, 2026

Outbreak of Legionnaires’ Disease Linked to Newly Installed Residential Water Heaters, the Netherlands, 2022–2023

Clinical Context

We think this might be relevant to the clinical guidance for ELN 2022 Risk Stratification (AML).

ELN 2022European LeukemiaNet Risk Recommendations

Favorable Risk Markers

Adverse Risk Markers

Awaiting Genetic Profile

The ELN 2022 risk groups help predict outcomes and guide the need for allogeneic stem cell transplant.

Hierarchical Summary

Favorable: NPM1 mut, CEBPA mut, CBF
Intermediate: FLT3-ITD without NPM1
Adverse: TP53, complex karyotype, MR genes

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with a newly diagnosed AML.

To guide the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in first remission.

To identify patients who benefit from targeted additions (e.g., Midostaurin, Gemtuzumab Ozogamicin) to standard 7+3 induction.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Who Icc 2022 Aml, MRD Assessment Threshold Interpreter or the CLL-IPI to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Recent Journal Updates

ELN 2022 Risk (AML)

Favorable Risk Markers

Adverse Risk Markers

When to Use

Clinical Use

Related Scores in Practice

Related Oncology Tools

Recent Journal Updates

ELN 2022 Risk (AML)

Favorable Risk Markers

Adverse Risk Markers

When to Use

Clinical Use

Related Scores in Practice

Related Oncology Tools